DanCann Pharma A/S (NGM:DANCAN)
Sweden
· Delayed Price · Currency is SEK · Price in DKK 0.444
-0.008 (-1.77%)
At close: Dec 4, 2025
DanCann Pharma Income Statement
Financials in millions DKK. Fiscal year is January - December.
Millions DKK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Revenue | 4.01 | 7.37 | 7.15 | 7.19 | 2.31 | - | Upgrade
|
| Revenue Growth (YoY) | -49.97% | 3.06% | -0.50% | 211.89% | - | - | Upgrade
|
| Cost of Revenue | 7.09 | 7.77 | 10.88 | 12.9 | 8.8 | 2.84 | Upgrade
|
| Gross Profit | -3.08 | -0.4 | -3.72 | -5.71 | -6.49 | -2.84 | Upgrade
|
| Selling, General & Admin | 4.76 | 4.77 | 9.45 | 8.52 | 7.12 | 2.94 | Upgrade
|
| Other Operating Expenses | -0.04 | -0.04 | -0.28 | -0.04 | - | - | Upgrade
|
| Operating Expenses | 6.71 | 6.76 | 56.39 | 10.71 | 8.01 | 3.04 | Upgrade
|
| Operating Income | -9.79 | -7.15 | -60.12 | -16.42 | -14.51 | -5.87 | Upgrade
|
| Interest Expense | -0.42 | -1.33 | -2.33 | -3.02 | -1.26 | -0.14 | Upgrade
|
| Interest & Investment Income | 0.24 | 0.14 | 0.2 | 1.19 | 0.58 | 0.02 | Upgrade
|
| Pretax Income | -9.98 | -8.35 | -62.24 | -18.25 | -15.19 | -5.99 | Upgrade
|
| Income Tax Expense | - | - | 0.02 | -2.19 | -3.44 | -1.73 | Upgrade
|
| Net Income | -9.98 | -8.35 | -62.26 | -16.06 | -11.75 | -4.26 | Upgrade
|
| Net Income to Common | -9.98 | -8.35 | -62.26 | -16.06 | -11.75 | -4.26 | Upgrade
|
| Shares Outstanding (Basic) | 6 | 4 | 0 | 0 | 0 | - | Upgrade
|
| Shares Outstanding (Diluted) | 6 | 4 | 0 | 0 | 0 | - | Upgrade
|
| Shares Change (YoY) | 374.48% | 2718.02% | 117.84% | 187.73% | - | - | Upgrade
|
| EPS (Basic) | -1.71 | -2.09 | -439.60 | -247.08 | -520.00 | - | Upgrade
|
| EPS (Diluted) | -1.71 | -2.09 | -439.60 | -247.08 | -520.00 | - | Upgrade
|
| Free Cash Flow | -3.01 | -5.24 | -12.04 | -12.74 | -18.36 | -11.68 | Upgrade
|
| Free Cash Flow Per Share | -0.52 | -1.31 | -85.03 | -195.89 | -812.31 | - | Upgrade
|
| Gross Margin | -76.76% | -5.37% | -52.03% | -79.44% | -281.73% | - | Upgrade
|
| Operating Margin | -244.00% | -97.03% | -840.42% | -228.38% | -629.41% | - | Upgrade
|
| Profit Margin | -248.89% | -113.21% | -870.40% | -223.45% | -509.76% | - | Upgrade
|
| Free Cash Flow Margin | -75.09% | -71.03% | -168.35% | -177.16% | -796.31% | - | Upgrade
|
| EBITDA | -7.79 | -5.13 | -56.74 | -14.19 | -13.62 | -5.78 | Upgrade
|
| EBITDA Margin | -194.29% | -69.55% | - | -197.34% | - | - | Upgrade
|
| D&A For EBITDA | 1.99 | 2.03 | 3.38 | 2.23 | 0.89 | 0.09 | Upgrade
|
| EBIT | -9.79 | -7.15 | -60.12 | -16.42 | -14.51 | -5.87 | Upgrade
|
| EBIT Margin | -244.00% | -97.03% | - | -228.38% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.